TRC 101

Drug Profile

TRC 101

Alternative Names: TRC-101

Latest Information Update: 29 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tricida
  • Class Small molecules; Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Renal failure

Most Recent Events

  • 28 Sep 2017 Phase-III clinical trials in Renal failure (In adults, In the elderly) in Hungary, Slovenia (PO) (EudraCT2016-003825-41)
  • 28 Sep 2017 Phase-III clinical trials in Renal failure (In the elderly, In adults) in Georgia (PO) (EudraCT2016-003825-41)
  • 10 Jan 2017 Efficacy and adverse events data from a phase I/II trial in Chronic Kidney Disease released by Tricida
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top